Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
via glucuronidation (30–50%): valproic acid β-O-glucuronide via beta oxidation (>40%): 2E-ene-valproic acid, 2Z-ene-valproic acid, 3-hydroxyvalproic acid, 3-oxovalproic acid via omega oxidation: 5-hydroxyvalproic acid, 2-propyl-glutaric acid some others: 3E-ene-valproic acid, 3Z-ene-valproic acid, 4-ene-valproic acid, 4-hydroxyvalproic acid All in all, over 20 metabolites are known. In adult patients taking valproate alone, 30–50% of an administered dose is excreted in urine as the glucuronide conjugate. The other major pathway in the metabolism of valproate is mitochondrial beta oxidation, which typically accounts for over 40% of an administered dose. Typically, less than 20% of an administered dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose of valproate is excreted unchanged (i.e., as valproate) in urine. Only a small amount is excreted via the faeces. Elimination half-life is 16±3 hours and can decrease to 4–9 hours when combined with enzyme inducers.
=== Chemicals and semiconductors === Ajinomoto has developed mild cleansing agents such as Amisoft and Amilite, and humectant emollients such as Eldew and Amihop. It also manufactures for companies such as Daiichi Sankyo Healthcare Co., Ltd. to develop products like the moisturizing detergent Minon. Ajinomoto developed its resin functional materials business using technology obtained through the production of MSG. Ajinomoto developed the Ajinomoto build-up film (ABF) substrate for insulating materials in semiconductor packages in high-performance CPUs. It was developed from the basic research on applications of amino acid chemistry to epoxy resins and their composites. ABF holds 90% of the market for this product.
In December 1978, Gaddafi stepped down as Secretary-General of the GPC, announcing his new focus on revolutionary rather than government activities; this was part of his new emphasis on separating the apparatus of the revolution from government. Although no longer in a formal government post, he adopted the title of "Leader of the Revolution" and continued as commander-in-chief of the armed forces. Historian Dirk Vandewalle stated that despite the Jamahariya's claims to being a direct democracy, Libya remained "an exclusionary political system whose decision-making process" was "restricted to a small cadre of advisers and confidantes" surrounding Gaddafi. Libya started constructing a welfare state. In March 1978, the government issued guidelines for housing redistribution, attempting to ensure every adult owned their own home. Most families were banned from owning more than one house, while former rental properties were expropriated by the state and sold to the tenants at a heavily subsidized price. In September, Gaddafi called for the People's Committees to eliminate the "bureaucracy of the public sector" and the "dictatorship of the private sector"; the People's Committees took control of several hundred companies, converting them into worker cooperatives run by elected representatives. In March 1979, the GPC announced the separation of government and revolution, the latter being represented by new Revolutionary Committees, who operated with the People's Committees in schools, universities, unions, the police force, and the military.
=== Ha–He === James Haber (b. 1943). American molecular biologist at Brandeis University known for his discoveries in the field of DNA repair. Member Natl. Acad. Sci. USA. J. B. S. Haldane (John Burdon Sanderson Haldane, 1892–1964). British (and later Indian) geneticist, biochemist (study of enzymes) and statistician, at University College London and at the end of his life at the Indian Statistical Institute. Apart from his contributions to science, he was notable for political activism and wrote many articles for the Daily Worker. Gordon Hammes (b. 1934). American biochemist at Cornell and Duke University, noted for work on enzyme mechanisms and kinetics. Member Natl. Acad. Sci. USA. Philip Handler (1917–1981). American nutritionist and biochemist, noted for the understanding of nicotinic acid deficiency and the discovery of the tryptophan-nicotinic acid relationship. He was at Duke University until he became President of the Natl. Acad. Sci. USA Jean Hanson (1919–1973). British biophysicist and zoologist at Massachusetts Institute of Technology known for her contributions to muscle research. Arthur Harden FRS (1865–1940). British biochemist at the Lister Institute, known for work on the fermentation of sugar and fermentative enzymes. Nobel Prize in Chemistry (1929). Grahame Hardie FRS (b. 1950), British biochemist at the University of Dundee, known for work on AMP-activated protein kinase. Harry Harris FRS, FCRP (1919–1994), British-born biochemist who showed that human genetic variation was not rare. Edwin B.
The two substrates of this enzyme are D-sorbitol and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are L-sorbose (shown in open-chain keto form), reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-glucitol:NADP+ oxidoreductase. This enzyme is also called Sou1p.
Sources: en.wikipedia.org
== Structure == The human ADM gene is localized to a single locus on Chromosome 11 with 4 exons and 3 introns. The ADM gene initially codes for a 185-amino acid precursor peptide, that can be differentially excised to form a number of peptides, including an inactive 53-amino acid AM, e PAMP, adrenotensin and ADM95-146. Mature human ADM is activated to form a 52-amino acid, 6-amino acid ring, that shares moderate structural similarity to the calcitonin family of regulatory peptides (calcitonin, CGRP and amylin). Circulating ADM consists of both the amidated active form (15%) and the glycated inactive form (85%). It has a plasma half-life of 22min, a mean clearance rate of 27.4 mL/kg/min, and an apparent volume of distribution of 880 ± 150 mL/kg. Adrenomedullin consists of 52 amino acids, has 1 intramolecular disulfide bond, and shows a slight homology with the calcitonin gene-related peptide (CGRP). The precursor, called preproadrenomedullin, consists of 185 amino acids and can be cleaved by plasma kallikrein at the Lys-Arg and Arg-Arg sites. By RNA-blot analysis, human adrenomedullin mRNA was found to be expressed in all tissues, and most highly expressed in the placenta, fat cells, lung, pancreatic islets, smooth muscle, and skin.
A gonadotropin-releasing hormone agonist (GnRH agonist) is a GnRH modulator that activates the GnRH receptor resulting in increased secretion of FSH and LH. Initially it was thought that GnRH agonists could be used as potent and prolonged stimulators of pituitary gonadotropin release, but it was soon recognized that GnRH agonists, after their initial stimulating action – termed a "flare" effect – eventually caused a paradoxical and sustained drop in gonadotropin secretion. This second effect was termed "downregulation" and can be observed after about 10 days. While this phase is reversible upon stopping the medication, it can be maintained when GnRH agonists use is continued for a long time. GnRH agonists can also be administered in a pulsatile manner through the use of a pump to produce a long-term stimulation of gonadotropin secretion, for instance to induce puberty.
=== General Features === Recently emerged de novo genes differ from established genes in a number of ways. Across a broad range of species, young and/or taxonomically restricted genes have been reported to be shorter in length than established genes, more positively charged, faster evolving, and to be less expressed. Although these trends could be a result of homology detection bias, a reanalysis of several studies that accounted for this bias found that the qualitative conclusions reached were unaffected. Another feature includes the tendency for young genes to have their hydrophobic amino acids more clustered near one another along the primary sequence. The expression of young genes has also been found to be more tissue- or condition-specific than that of established genes. In particular, relatively high expression of de novo genes was observed in male reproductive tissues in Drosophila, stickleback, mice, and humans, and, in the human brain. In animals with adaptive immune systems, higher expression in the brain and testes may be a function of the immune-privileged nature of these tissues. An analysis in mice found specific expression of intergenic transcripts in the thymus and spleen (in addition to the brain and testes). It has been proposed that in vertebrates de novo transcripts must first be expressed in tissues lacking immune cells before they can be expressed in tissues that have immune surveillance.
David eventually returns to Lanford and tells Darlene he wants to reenter his children's lives. After sleeping together, both Darlene and David consider reconciling until Roseanne tells Darlene the reason David said he left their marriage. She says it would be bad for their children, who resent David being an absent father. At Dan's urging, David agrees to get his life settled before seeing the kids again. In The Conners, David is working at Trader Joe's and has moved in with a free-spirited woman named Blue. Darlene is furious to discover that during the kids' first weekend staying with David, Blue allowed Harris' boyfriend to sleep over and she lost her virginity. David defensively says he was working and was unaware, but Darlene demands he be a more attentive father. David eventually breaks up with Blue because she wants children. David and Darlene began sleeping together again while Darlene is also in a relationship with Ben. Darlene decides she wants to be with Ben, and she and David finally agree to divorce. Ben, already knowing the two were seeing each other, breaks up with Darlene, though he eventually forgives her. David began seeing a therapist, and, during a joint session with Darlene, reveals he feels Darlene never treated him as an equal and caused him to leave her. When David was first introduced to the series, his name was Kevin, though it was subsequently changed to David. While applying for college, he uses his full name, David Maurice Healy. As a show inside joke, Roseanne comments in Season 6, "David's not even his real name.
This term can then define the residual enzymatic activity present when the inhibitor is interacting with individual enzymes in the population. However the inclusion of this term has the added value of allowing for the possibility of activation if the secondary Vmax term turns out to be higher than the initial term. To account for the possibly of activation as well the notation can then be rewritten replacing the inhibitor "I" with a modifier term (stimulator or inhibitor) denoted here as "X".
Sources: en.wikipedia.org
==== Antagonists ==== Cyclazocine Diprenorphine Levallorphan Nalodeine Nalorphine Naloxone Naltrexone Samidorphan Note that some of the above drugs may actually be very weak partial agonists rather than silent antagonists.
=== 24 April === Russian forces stopped an attack on the Black Sea Fleet base at Sevastopol. The Russian defence ministry said that "three unmanned high-speed boats" were destroyed. Ukraine did not comment on the attack.
A = 1HPN (all IdoA(2S) residues in 2S0 conformation) Jmol viewer B = van der Waals radius space-filling model of A C = 1HPN (all IdoA(2S) residues in 1C4 conformation) Jmol viewer D = van der Waals radius space-filling model of C In these models, heparin adopts a helical conformation, the rotation of which places clusters of sulfate groups at regular intervals of about 17 angstroms (1.7 nm) on either side of the helical axis.
HBTU (hexafluorophosphate benzotriazole tetramethyl uronium) is a coupling reagent used in solid phase peptide synthesis. It was introduced in 1978 and shows resistance against racemization. It is used because of its mild activating properties. HBTU is prepared by reaction of hydroxybenzotriazole with TCFH under basic conditions and was assigned to a uronium type structure, presumably by analogy with the corresponding phosphonium salts, which bear a positive carbon atom instead of the phosphonium residue. Later, it was shown by X-ray analysis that salts crystallize as guanidinium rather than the corresponding uronium salts.
Due to its sedative and tranquilizing properties, it was used to quiet the minds of those with psychosis, help with people who were considered insane, and also to help treat patients with insomnia. However, despite its medicinal values in these cases, it was noted that in cases of psychosis, it could cause anger or depression, and due to the drug's euphoric effects, it could cause depressed patients to become more depressed after the effects wore off because they would get used to being high. The standard medical use of opium persisted well into the 19th century. US president William Henry Harrison was treated with opium in 1841, and in the American Civil War, the Union Army used 175,000 lb (80,000 kg) of opium tincture and powder and about 500,000 opium pills. During this time of popularity, users called opium "God's Own Medicine". One reason for the increase in opiate consumption in the United States during the 19th century was the prescribing and dispensing of legal opiates by physicians and pharmacists to women with "female complaints" (mostly to relieve menstrual pain and hysteria). Because opiates were viewed as more humane than punishment or restraint, they were often used to treat the mentally ill. Between 150,000 and 200,000 opiate addicts lived in the United States in the late 19th century and between two-thirds and three-quarters of these addicts were women. Opium addiction in the later 19th century received a hereditary definition. Dr.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.